about
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialTreatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptideNatural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patientsPalliative treatment of malignant ascites: profile of catumaxomab.Peritoneovenous shunting for nongynecologic malignant ascites.Malignant ascites: pathophysiology and treatment.The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascitesNovel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab).Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report.How valuable is ascitic cytology in the detection and management of malignancy?Feasibility of externalized peritoneovenous shunt (EPVS) for malignant ascitesManagement of ascites due to gastrointestinal malignancy.Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cellsMalignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures.Advantages of assaying telomerase activity in ascites for diagnosis of digestive tract malignanciesDeterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone.Ascitic complement system in ovarian cancerDiagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites.Symptom management in gynecologic malignancies.Catumaxomab: in malignant ascites.Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.A Novel Combination of C-Reactive Protein and Vascular Endothelial Growth Factor in Differential Diagnosis of Ascites.Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study.Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells.The clinical significance of vascular endothelial growth factor in malignant ascites.Prognostic significance of new onset ascites in patients with pancreatic cancer.Tc99m-MDP uptake in ascitic fluid in a patient with prostate carcinoma: A clue to detect metastases.Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis.MELD-sodium score and its prognostic value in malignancy-related ascites of pancreatic and gastric cancer.Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility.Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients.Therapeutic effects of antimicrobial peptide on malignant ascites in a mouse model.
P2860
Q24629295-0F1CFA9D-C05D-45BF-8CCE-1A20F1CB4470Q24796110-5C2E21CF-76C8-4C49-ADD6-0E3B8592CBD6Q33754724-7F2D3810-B3C0-444A-8265-01BDDB2C9375Q33885497-5B6C3F10-7AD4-4621-BE9A-092D85A1F421Q33892606-D20F7ABD-443B-4256-8750-8FDD42C27B89Q34205749-5FB72DD4-8C42-4A43-B775-7D5A8518ECB6Q34213359-3CEAA648-0597-45A4-8C74-F635037C5DD5Q34769958-23DC1C89-94BB-4751-987E-EFBA4B839598Q35057971-2859F171-D8E1-471A-A76D-E3EF5F066BA8Q35079157-36F2EDAE-34BF-4936-8512-1859CAE1A69AQ35143498-267E9EBB-BE87-4E34-BD20-C494EA28AE24Q35168699-908EE14C-E373-42B4-8EE4-B0350B37143CQ35789515-39039D80-C627-4154-BFF5-360BE0563701Q35811043-72CB51AE-4865-4681-B39C-714371734D33Q35957129-6728E9A7-1E45-40D3-9CA6-31D849F815C1Q36065671-629E510B-C622-435C-8CB5-6BACD3112AE0Q36112029-304AA545-BFEB-42BC-9627-BBC91B7BA5F8Q36616364-822A1377-6E34-4A76-A03D-120E511B574AQ36639217-83E8F6BB-7591-4DF4-8CB4-AE68545DF193Q37909369-8100AB45-E35C-4965-A7AE-585899858F39Q38016957-566B87A3-B2D2-47D0-A0C6-8EE72A65F5E1Q38183786-80D10683-94E0-42BF-922D-38A732305FA9Q38855207-62697C5F-409D-4D18-A645-2C756B4AE41EQ40202331-362DFFFA-431A-42E5-B016-EA88A3B1EAE0Q40401963-963395F9-CE96-4D56-9B59-9E693FF09978Q40436743-27677E33-B41D-494B-8726-9E2D0DBCF0D9Q42383717-5F7756CC-8F49-437A-80AF-E77FBC75220BQ42710496-B161B591-A1BB-4DD7-B75B-37414261F6EBQ44230207-21CA3471-ABA6-4A3B-B509-73D9CF6A5E8BQ46439804-AD0CE00F-15ED-45BB-A441-2E3B69C02BCCQ48167974-1071216A-D026-40BB-B2BA-BC82DB9BC4BFQ50769683-87CF5DEE-BD3D-4EC1-8338-142D47648154Q55396474-9EF5060A-EECA-41AF-BA87-B94DF73C12DE
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Malignant ascites.
@en
type
label
Malignant ascites.
@en
prefLabel
Malignant ascites.
@en
P2093
P2860
P356
P1476
Malignant ascites.
@en
P2093
P2860
P356
10.1002/BJS.1800830104
P407
P577
1996-01-01T00:00:00Z